Shares in Arcutis Biotherapeutics (NASDAQ: ARQT) soared by almost 30% in trading to 10:30 a.m. ET today. The move comes after ...

Experts discuss the impact of severe eczema on children’s daily lives and the role of newer non-steroidal topical therapies ...

Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and ...

Skin conditions with Parkinson’s disease are common and manageable. By paying attention to these symptoms, patients can ...

This article was reviewed by Knox Beasley, MD. Exosomes for Hair Loss: Costs, Safety, Efficacy, & Benefits The deeper you research options for hair loss treatments, … ...

New clinical data demonstrate Zoryve's effectiveness in treating atopic dermatitis, reducing sleep disruptions and maintaining disease control with minimal adverse events across all ages.

Arcutis Biotherapeutics has recently seen its consensus analyst price target hold steady at $23.38, even as expectations around its risk profile and growth have shifted slightly. This stability comes ...

Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.

It’s Eczema Awareness Month, and dermatologist Dr Bernard Ho explains why this often misunderstood condition is more than ...